Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

Polyneuropathy in p.V142I hereditary transthyretin amyloidosis: Diagnostic challenges and clinical considerations.

Journal of the neurological sciences·2026
Same author

Corrigendum to 'Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20' [Journal of the Neurological Sciences, 486 (2026) 125918].

Journal of the neurological sciences·2026
Same author

Prevalence and attribution of polyneuropathy in p.V142I (V122I) hereditary transthyretin amyloidosis.

Journal of the neurological sciences·2026
Same author

Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review.

JACC. CardioOncology·2026
Same author

Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20.

Journal of the neurological sciences·2026

Related Experiment Video

Updated: Sep 6, 2025

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

2.8K

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Five New Things.

Chafic Karam1

  • 1Department of Neurology, University of Pennsylvania, Philadelphia.

Neurology. Clinical Practice
|June 24, 2022
PubMed
Summary
This summary is machine-generated.

This review updates on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), highlighting revised diagnostic guidelines and expanding treatment options. Emerging biomarkers show promise for future CIDP management.

More Related Videos

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
08:57

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

2.2K
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

9.5K

Related Experiment Videos

Last Updated: Sep 6, 2025

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

2.8K
In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
08:57

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

2.2K
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

9.5K

Area of Science:

  • Neurology
  • Clinical Neuroscience

Background:

  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves.
  • Accurate diagnosis and effective treatment are crucial for managing CIDP and preventing disability.

Purpose of the Study:

  • To provide a comprehensive update on recent advancements in the diagnosis and treatment of CIDP.
  • To discuss new guidelines, emerging biomarkers, and therapeutic strategies for CIDP.

Main Methods:

  • Review of recent literature and guidelines pertaining to CIDP.
  • Analysis of new diagnostic criteria and therapeutic approaches.
  • Exploration of novel biomarkers and their potential clinical applications.

Main Results:

  • The 2021 European Academy of Neurology/Peripheral Nerve Society guideline revision offers updated diagnostic criteria for CIDP.
  • Research is exploring novel antibodies and serum neurofilament light chain as potential biomarkers.
  • Treatment options for CIDP are expanding, with ongoing studies into new therapies.

Conclusions:

  • CIDP diagnostic criteria are continually refined, leading to improved classification and exclusion of mimics.
  • Advances in understanding CIDP pathogenesis are driving the development of more targeted and effective treatments.
  • The study of biomarkers like neurofilament light chain holds promise for earlier diagnosis and personalized therapy in CIDP.